Bobby Soni
Partner @ IP Group
London, United Kingdom
Bobby Soni is a convertible note investor at IP Group in London focused on Biotechnology and Medical. Bobby joined Novo A/S in January 2009 as Principal in Novo Seeds.Bobby obtained his BS in Biochemistry from the University of Rochester in 1992 and his PhD degree in Biology from the University of Virginia in 1998. His PhD research was primarily conducted at Imperial College of Science, London and was published in leading scientificjournals.Prior to joining Novo Seeds, Bobby was Discovery Licensing Manager at LEO Pharma where he was responsible for preclinical stage licensing and out-sourcing. During his tenure, Bobby was instrumental in designing and implementing LEO Pharma's drug discovery out-sourcing strategy. Before then, Bobby was a Project Leader and Principal Scientist at Maxygen ApS.Bobby serves on the Board of Directors of the biotech companies Acesion Pharma (Chairman), Concit Pharma and C10 Pharma.
- Total investments:
- 40
- Last investment:
- Lead investor:
- 95%
Last updated:
For AI agents: llms.txt
Industries Bobby Soni invests in
Stages Bobby Soni invests in
Countries Bobby Soni invests in
Investment Focus
Industry
- Biotechnology 21 (53%)
- Medical 10 (25%)
- Health Care 9 (23%)
- Therapeutics 5 (13%)
- Medical Device 5 (13%)
Stage
- Convertible Note 21 (53%)
- Pre-Seed 10 (25%)
- Debt Financing 4 (10%)
- Seed 2 (5%)
- Series A 1 (3%)
Country
- Denmark 22 (55%)
- Germany 2 (5%)
- Switzerland 2 (5%)
- The Netherlands 2 (5%)
- Norway 1 (3%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Zeta Diagnostics
|
First-in-class hardware-and-software-as-a-service diagnostics for the 400M suffering from middle ear problems | $530K / Pre-Seed / Feb 28, 2024 | |
Solid Therapeutics
|
Solid Therapeutics develops novel cancer therapeutics with dual performance targeting cancer cells and immune cells to treat solid tumors. | Convertible Note / Sep 05, 2023 | |
HHC Medical
|
HHC Medical is a health tech company developing targeted non-invasive drug delivery devices through electroporation to transfect a large number of cells. It was founded in 2019 and is headquartered in Hillerød, Denmark. | Convertible Note / Sep 05, 2023 | |
FimmCyte
|
FimmCyte develops a novel disease modifying treatments for fibro-inflammatory diseases, starting with Endometriosis. | Sep 05, 2023 | |
TriptoBIO
|
TriptoBIO is a biotechnology research company developing a platform for producing natural plant compounds. Its platform utilizes synthetic biology techniques to produce a class of plant compounds, called diterpenoids, through fermentation, allowing novel applications of plant diterpenoids while avoiding intensive plant farming and petrochemicals. | $539.6K / Convertible Note / Sep 04, 2023 | |
Rapidemic
|
Rapidemic develops a molecular point-of-care test for the diagnosis of sexually transmitted infections. Their proprietary technology increases the sensitivity and specificity of the reaction while keeping manipulations to a minimum. Its technology enables low-temperature diagnostics while safeguarding accuracy and reducing false positives. | $549K / Convertible Note / Aug 31, 2023 | |
BioHalo
|
BioHalo is transforming the halogenated chemicals industry by developing more sustainable and bio-based fluorinated polymers and high-performance materials. | $542.1K / Convertible Note / Aug 31, 2023 | |
Amalus Therapeutics
|
Amalus Therapeuticss' objective is to significantly improve the lives of those suffering from cancer and fibrotic disorders. | $542.1K / Convertible Note / Aug 31, 2023 | |
Leopard Biosciences
|
Leopard Biosciences is democratizing diagnostics by putting molecular testing power in the hands of doctors and patients at the point of treatment. | $549K / Convertible Note / Aug 31, 2023 | |
Aiomic
|
Aiomic is a HealthTech company developing AI-enhanced reporting and prediction tools to combat postoperative complications. It offers automated tracking and real-time risk assessment using the company's Surgical Advanced Warning (SAW) system that functions as a business intelligence tool for hospitals, a decision support tool for healthcarepractitioners, and an individualized patient empowerment tool by allowing patients to gain insight into their risk profiles. | Convertible Note / Mar 16, 2023 | |
| See all 40 investments → | |||
Co-Investors
About IP Group
IP Group's core business is the creation of value for its shareholders and partners through the commercialisation of intellectual property originating from research intensive institutions. Their strength lies in managing this process from finding suitable intellectual property to commercialise to either helping develop businesses and createvalue out of them, or identifying and establishing appropriate commercial partnerships to do so. IP Group's extensive expertise in this area combined with its inside knowledge of both industry and finance have enabled the group to create a formidable track record of consistently delivering excellent results for their companies, for their partners and for their shareholders.
IP Group Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Ben Murphey
Investment Director
|
|||
Dani Bach
Partner, Life Sciences
|
|||
Greg Smith
Chief Financial Officer
|
|||
Jamie Vollbracht
Partner, Cleantech
|
|||
Manjari Chandran-Ramesh
Investment Director
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Bobby Soni invest in?
Bobby Soni invests primarily in Biotechnology, Medical and Health Care startups, most often at Convertible Note and Pre-Seed stage. Most of the 40 investments tracked by Shizune back companies in Denmark. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Bobby Soni last invest?
The most recent investment recorded for Bobby Soni closed in Feb 2024. Shizune tracks 40 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
